Sarah L. Bermingham

Sarah L. Bermingham

Auto-generated profile, based on publicly available information

Sarah L. Bermingham

Takeda Development Center Americas, Inc. , Cambridge, MA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SBSarah L. Bermingham
Sarah L. Bermingham
ASAlexander Spalding
Alexander Spalding
EBElisabeth Bennett
Elisabeth Bennett
DPDavid T. Plante
David T. Plante
Introduction: Understanding the experience and impact of idiopathic hypersomnia (IH) is critical for improving diagnosis, treatment, research, drug development, and policy awareness. Currently, physician and researcher perspectives dominate the discourse on IH, often overlooking the lived experiences of those with the condition. Objective: To understand the lived experience of IH from the patient perspective by analyzing spontaneously generated online patient-experience data. Methods: Publicly available data were collected through iterative Google searches, manually coded, and thematically analyzed using inductive and deductive approaches to qualitative content analysis. Concept saturation was reached, ensuring comprehensive theme exploration. Results: Searches identified 346 social media posts, community forums, blogs, videos, and podcasts created by 123 people with self-identified IH between 2012 and 2022. Most were female, 16–60 years old, and lived in the United States, Australia, Europe, and Canada. Symptom experiences were grouped under 10 themes: prolonged sleep, never feeling fully awake, relentless sleepiness, non-restorative sleep, difficulty in waking, automatic behavior, microsleeps and prolonged naps, cognitive difficulties, limited physical energy, and vivid dreams and hypnogogic hallucinations. Life impacts were identified and grouped under seven domains: psychological and emotional well-being, activities of daily living, injuries, relationships, work and school, physical health, and healthcare and treatment burden. Discussion: This study expands the understanding of IH beyond clinician and researcher-driven perspectives and clinical descriptions and illuminates its profound impact on all aspects of life from patients’ point of view. These insights can help clinicians provide better care, drive patient-centered drug development, and raise awareness of this devastating disorder.

8 July 2026 in SLEEP Advances
Verified
Journal Article
Open access
SGSomraj Ghosh
Somraj Ghosh
SCStephen Crawford
Stephen Crawford
SBSarah L Bermingham
Sarah L Bermingham
MZMiriam L Zichlin
Miriam L Zichlin
FSFiona Stewart
Fiona Stewart
KKKristin Kistler
Kristin Kistler
The symptoms experienced by people with narcolepsy and idiopathic hypersomnia (IH) have profound effects on individuals’ lives, affecting daily functioning, relationships and mental health, and can impair performance at work or school. Although numerous studies have evaluated the impact of narcolepsy and IH on work-related outcomes, the evidence base is highly fragmented and difficult to meaningfully summarize. We conducted a systematic literature review of published evidence to better understand the impact of these disorders on employment, work productivity, work satisfaction, and related outcomes. We identified 54 publications representing 51 unique studies that met the study inclusion criteria and were included in the review. Although most people with narcolepsy or IH were employed, fewer were in paid work than control populations, and absenteeism and presenteeism were high. Having narcolepsy and IH resulted in lower wages and missed work time, leading to unfavorable impacts on career progression, promotion, job satisfaction, and income. The most frequently reported work-related problems were sleepiness at work, reduced performance, work accidents, and lateness. More severe excessive daytime sleepiness was associated with greater work impairment. Narcolepsy-specific medications that improved excessive daytime sleepiness were reported to improve work productivity in clinical trials; however, many people are left with substantial residual impairment despite treatment. These findings indicate that narcolepsy and IH impose a substantial burden on work functioning and employment, and there is a need for more research to inform interventions and policies aimed at mitigating the impact of these debilitating conditions on individuals’ professional lives.

18 August 2026 in SLEEP
Verified
Journal Article
Open access
RTRaul Torres
Raul Torres
RGRahul Ghosal
Rahul Ghosal
MNMelissa Naylor
Melissa Naylor
SGSimerpal K Gill
Simerpal K Gill
YPYelena Pyatkevich
Yelena Pyatkevich
DVDmitri Volfson
Dmitri Volfson
Study Objectives: Excessive daytime sleepiness is a defining symptom of narcolepsy, affecting daily functioning and quality of life. We developed and evaluated an actigraphy-based nap detection algorithm to objectively estimate daytime naps, a key manifestation of excessive daytime sleepiness. Materials and Methods: The nap detection algorithm was developed using data from the Multi-Ethnic Study of Atherosclerosis. This dataset included manually annotated naps from 2237 participants with 7 days of wrist-worn actigraphy. The nap detection algorithm was then applied in studies of participants with narcolepsy type 1 (NT1). Results: Our final nap detection algorithm yielded high specificity (Tau B: 93.2%) and accuracy (F1 Area: 83.9%). Applying our algorithm in an observational study (NCT04445129), participants with NT1 experienced 12.8 fewer nap-free days (p < .001) over 28 days and slept 34 minutes more (p < .001) during the day than controls. In a randomized clinical trial (NCT05687903), our algorithm demonstrated that participants with NT1 treated with an orexin receptor 2-selective agonist, oveporexton (TAK-861), experienced 6.1−11.9 additional nap-free days and slept 12−33 minutes fewer versus baseline. Conclusions: Overall, our nap detection algorithm retained sensitivity while minimizing false positives. It reliably identified nap-based phenotypes that differentiate individuals with NT1 from age and sex-matched healthy controls, and it demonstrated that an orexin receptor 2-selective agonist reduces napping in participants with NT1 to normative levels near those of healthy controls.